Skip to content

8-KAccepted Sep 28, 6:12 PM ET

Bayview Acquisition Corp Delisted from Nasdaq; Plans OTC Quotation

Bayview Acquisition Corp

Accepted (ET)

6:12 PM

Sep 28, 2026

Filed

Sep 29, 2026

Documents

12

Size

270.7 KB

Summary

Bayview Acquisition Corp Delisted from Nasdaq; Plans OTC Quotation

Updated

What Happened Bayview Acquisition Corp filed an 8-K (Sept. 29, 2026) reporting that Nasdaq’s Listing and Hearing Review Council affirmed a prior decision to delist the company’s securities because Bayview failed to complete its business combination with Oabay Inc. by the June 19, 2026 deadline. Nasdaq’s Hearings Panel had suspended trading effective at the open on July 7, 2026. Bayview expects Nasdaq to file a Form 25-NSE to remove its securities from Nasdaq and intends to pursue quotation of its Ordinary Shares and Rights on the OTC Markets under tickers “BAYA” and “BAYAR”; a market maker filed a Form 211 with FINRA on Sept. 16, 2026 to initiate an OTC Pink quotation.

Key Details

  • Nasdaq set a business-combination deadline of June 19, 2026; trading was suspended effective July 7, 2026.
  • Bayview asked Nasdaq for a deadline extension on July 17, 2026 and submitted an appeal memorandum on July 31, 2026; the Council affirmed the delisting on Sept. 22, 2026.
  • The company expects Nasdaq to file Form 25-NSE to remove its securities from Nasdaq and plans to seek OTC Pink quotation under tickers BAYA (Ordinary Shares) and BAYAR (Rights).
  • Bayview warns there may be a very limited market, limited quotes, and insufficient trading volume, which could adversely affect the trading price and liquidity of its securities.

Why It Matters For investors, delisting from Nasdaq typically means reduced visibility and liquidity: shares moving to the OTC Pink market often trade less frequently, with wider bid-ask spreads and potentially greater price volatility. The company’s failure to close the announced business combination with Oabay was the stated cause of the delisting. Bayview’s planned OTC quotation may allow continued trading, but the filing says there is no assurance of active quotes or sufficient volume, which can make it harder to buy or sell shares at favorable prices. The 8-K also contains standard forward-looking disclaimers; Bayview isn’t required to update those statements.

AI-written summary · check the filing